BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 16980809)

  • 21. [Neurological manifestations of Fabry disease].
    Mendióroz M; Fernández-Cadenas I; Montaner J
    Rev Neurol; 2006 Dec 16-31; 43(12):739-45. PubMed ID: 17160925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anderson-Fabry disease and the heart.
    O'Mahony C; Elliott P
    Prog Cardiovasc Dis; 2010; 52(4):326-35. PubMed ID: 20109602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The management and treatment of children with Fabry disease: A United States-based perspective.
    Hopkin RJ; Jefferies JL; Laney DA; Lawson VH; Mauer M; Taylor MR; Wilcox WR;
    Mol Genet Metab; 2016 Feb; 117(2):104-13. PubMed ID: 26546059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cutaneous complications of Anderson-Fabry disease.
    Giuseppe P; Daniele R; Rita BM
    Curr Pharm Des; 2013; 19(33):6031-6. PubMed ID: 23448454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease.
    Germain DP; Altarescu G; Barriales-Villa R; Mignani R; Pawlaczyk K; Pieruzzi F; Terryn W; Vujkovac B; Ortiz A
    Mol Genet Metab; 2022; 137(1-2):49-61. PubMed ID: 35926321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.
    Banikazemi M; Ullman T; Desnick RJ
    Mol Genet Metab; 2005 Aug; 85(4):255-9. PubMed ID: 15939645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fabry disease: Review and experience during newborn screening.
    Hsu TR; Niu DM
    Trends Cardiovasc Med; 2018 May; 28(4):274-281. PubMed ID: 29100912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.
    Lidove O; West ML; Pintos-Morell G; Reisin R; Nicholls K; Figuera LE; Parini R; Carvalho LR; Kampmann C; Pastores GM; Mehta A
    Genet Med; 2010 Nov; 12(11):668-79. PubMed ID: 20962662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fabry disease: cardiac manifestations and therapeutic options.
    Pierre-Louis B; Kumar A; Frishman WH
    Cardiol Rev; 2009; 17(1):31-5. PubMed ID: 19092368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Fabry disease : diagnosis and treatment].
    Üçeyler N; Sommer C
    Schmerz; 2012 Sep; 26(5):609-19. PubMed ID: 23052995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fabry disease (alpha-galactosidase A deficiency): renal involvement and enzyme replacement therapy.
    Desnick RJ; Wasserstein MP; Banikazemi M
    Contrib Nephrol; 2001; (136):174-92. PubMed ID: 11688379
    [No Abstract]   [Full Text] [Related]  

  • 32. Fabry disease in children and the effects of enzyme replacement treatment.
    Pintos-Morell G; Beck M
    Eur J Pediatr; 2009 Nov; 168(11):1355-63. PubMed ID: 19242721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.
    Schaefer RM; Tylki-Szymańska A; Hilz MJ
    Drugs; 2009 Nov; 69(16):2179-205. PubMed ID: 19852524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
    Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
    J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Management of Fabry disease].
    Constantin T; Székely A; Ponyi A; Gulácsy V; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Medvecz M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Rákóczi E; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G
    Orv Hetil; 2010 Aug; 151(31):1243-51. PubMed ID: 20656661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Current management of Fabry disease].
    Cochat P; Liutkus A; Dubourg L; Levade T
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S167-71. PubMed ID: 17373218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Fabry disease--guidelines for diagnosis and management of adult patients].
    Merkler M; Pećin I; Simić I; Muacević-Katanec D; Sućur N; Reiner Z
    Lijec Vjesn; 2014; 136(5-6):133-5. PubMed ID: 25154181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal complications of Fabry disease in children.
    Najafian B; Mauer M; Hopkin RJ; Svarstad E
    Pediatr Nephrol; 2013 May; 28(5):679-87. PubMed ID: 22898981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Results of enzyme replacement therapy in Fabry disease nephropathy].
    Dussol B
    Presse Med; 2007 Mar; 36 Spec No 1():1S43-7. PubMed ID: 17546767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fabry disease.
    Thomas AS; Hughes DA
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():88-101. PubMed ID: 25345090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.